- Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic2010 | Faculty of Physical Education and Sport, Faculty of Medicine in Hradec Králové
- Allogeneic stem cell transplantation can improve outcome of AML patients without complete cytogenetic response after induction and consolidation treatment2015 | Faculty of Medicine in Pilsen
- Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic2010 | First Faculty of Medicine
- Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials2013 | Publication without faculty affiliation
- Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications2013 | Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Development of acute myeloid leukemia associated with Ph-negative clone with inv(3)(q21q26) during imatinib therapy for chronic myeloid leukemia2009 | Faculty of Medicine in Pilsen
- Development of acute myeloid leukemia associated with Ph-negative clone with inv(3)(q21q26) during imatinib therapy for chronic myeloid leukemia2009 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Imatinib mesylate (Glivec) in treatment of chronic myeloid leukemia in chronic phase2004 | Faculty of Medicine in Hradec Králové, Central Library of Charles University
- Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery2009 | First Faculty of Medicine
- Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels2013 | Faculty of Medicine in Pilsen, Central Library of Charles University
- Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase2006 | First Faculty of Medicine
- Lenalidomide treatment in myelodysplastic syndrome with 5q deletion - Czech MDS group experience2015 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Second Faculty of Medicine
- Discontinuation of biological therapy with tyrosine kinase inhibitors in chronic myeloid leukemia patients2014 | Faculty of Medicine in Pilsen
- Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation2006 | Second Faculty of Medicine
- Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin +/- prednisone addition to lenalidomide in refractory or relapsed patients)2018 | First Faculty of Medicine
- The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients2018 | Faculty of Medicine in Hradec Králové
- Impact of age on the clinical response of patients with CML treated with imatinib2015 | Faculty of Medicine in Hradec Králové
- Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial2018 | Second Faculty of Medicine